IL6 and Alzheimer disease: Furthermore, the findings demonstrate that the neuroprotective effect of isorhamnetin involves mediation of the noncanonical IL-6 signaling pathway, thus indicating the potential of isorhamnetin for use in AD treatment (Figure 8).